Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ginkgo Bioworks Hldgs Inc (DNA)

Ginkgo Bioworks Hldgs Inc (DNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 561,907
  • Shares Outstanding, K 58,532
  • Annual Sales, $ 227,040 K
  • Annual Income, $ -547,030 K
  • EBIT $ -423 M
  • EBITDA $ -312 M
  • 60-Month Beta 1.48
  • Price/Sales 2.43
  • Price/Cash Flow N/A
  • Price/Book 0.80

Options Overview Details

View History
  • Implied Volatility 100.26% ( +2.98%)
  • Historical Volatility 96.67%
  • IV Percentile 28%
  • IV Rank 9.49%
  • IV High 354.68% on 08/19/24
  • IV Low 73.59% on 06/20/25
  • Put/Call Vol Ratio 0.26
  • Today's Volume 775
  • Volume Avg (30-Day) 1,331
  • Put/Call OI Ratio 0.15
  • Today's Open Interest 115,997
  • Open Int (30-Day) 112,650

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Sell
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -1.44
  • Number of Estimates 1
  • High Estimate -1.44
  • Low Estimate -1.44
  • Prior Year -3.20
  • Growth Rate Est. (year over year) +55.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.21 +18.88%
on 06/20/25
13.33 -26.78%
on 07/03/25
+1.21 (+14.15%)
since 06/17/25
3-Month
6.42 +52.02%
on 05/06/25
13.33 -26.78%
on 07/03/25
+1.91 (+24.33%)
since 04/17/25
52-Week
5.00 +95.20%
on 04/04/25
16.85 -42.08%
on 02/06/25
-3.53 (-26.57%)
since 07/17/24

Most Recent Stories

More News
Ginkgo Bioworks Launches ADME Profiling Service Using Lab Automation, Offering a US-based Operation That Will Match or Beat Pricing Quotes from Chinese or Other International Vendors

Ginkgo Bioworks launches cost-effective, high-throughput ADME profiling service to accelerate small molecule drug discovery with model-ready datasets

DNA : 9.76 (+1.67%)
Why Ginkgo Bioworks Holdings Stock Raced 9% Higher Today

The company is forging ahead with next-generation drug development solutions.

GOOGL : 183.58 (+0.33%)
GOOG : 184.70 (+0.51%)
DNA : 9.76 (+1.67%)
Down a Monstrous 90% This Year, Is There Any Hope Left for Ginkgo Bioworks Investors?

Could this beaten-down stock turn things around in the near future?

GOOGL : 183.58 (+0.33%)
GOOG : 184.70 (+0.51%)
NVO : 65.29 (-2.61%)
DNA : 9.76 (+1.67%)
MRK : 81.52 (-1.10%)
2 Big Risks and 2 Big Opportunities for Ginkgo Bioworks Stock

The risks may resolve in a year or so but seizing the opportunities will take longer.

DNA : 9.76 (+1.67%)
This 1 AI Stock Could Revolutionize Biotech and Pharma

The company is using artificial intelligence, and planning to help others use AI empowered by its data collection.

DNA : 9.76 (+1.67%)
Down 88% in 1 Year, What's Next for Ginkgo Bioworks Stock?

Its ambitious business model may not be sustainable.

DNA : 9.76 (+1.67%)
Down 86% This Year, Is Ginkgo Bioworks Stock a Bargain Now?

Have shares of the troubled life sciences business fallen too far?

DNA : 9.76 (+1.67%)
Prediction: Artificial Intelligence Will Lead to Higher Returns With Biotech Stocks

Efficiency in core processes is set to increase substantially due to AI.

DNA : 9.76 (+1.67%)
RXRX : 5.52 (+2.41%)
Down 81% in 2024, Is Ginkgo Bioworks Stock Still a Buy?

A recovery plan is underway, but it isn't a slam dunk.

DNA : 9.76 (+1.67%)
Why Ginkgo Bioworks Stock Is Sinking Today

There was double trouble for this beaten-down biotech stock.

ARKG : 24.49 (-1.57%)
DNA : 9.76 (+1.67%)
ARKK : 76.24 (+1.32%)

Business Summary

Ginkgo Bioworks platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo Bioworks, formerly known as Soaring Eagle Acquisition Corp., is based in NEW YORK.

See More

Key Turning Points

3rd Resistance Point 10.66
2nd Resistance Point 10.40
1st Resistance Point 10.08
Last Price 9.76
1st Support Level 9.51
2nd Support Level 9.25
3rd Support Level 8.93

See More

52-Week High 16.85
Fibonacci 61.8% 12.32
Fibonacci 50% 10.93
Last Price 9.76
Fibonacci 38.2% 9.53
52-Week Low 5.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar